NurExone Biologic

Company Overview

Snapshot

Founded in January 2020, NurExone Biologic operates with 11–50 employees. The company has raised $9.53M across 8 funding rounds and went public on TSXV in July 2022.

Business overview

NurExone Biologic is a Health Tech & Life Sciences company focused on revolutionizing recovery from nervous system injuries. The company develops a biological extracellular vesicles-based drug platform designed to treat damage in the Central Nervous System (CNS) by regenerating and rewiring neurons. Its novel approach utilizes intranasal exosome administration, offering an alternative to existing treatments for spinal cord injury (SCI). NurExone operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting the Life Sciences and Pharmaceutical industries.

Strategic signal

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing process, which strengthens its supply chain readiness. This patent signals a significant step in securing intellectual property for its core technology, enhancing its ability to scale production and potentially accelerate the development and commercialization of its EV-based drug platform for CNS injuries.

Company Intelligence Q&A

What is NurExone Biologic's primary focus?

NurExone Biologic is developing a revolutionary biological extracellular vesicles-based drug platform to treat damage in the Central Nervous System (CNS) by regenerating and rewiring neurons.

When did NurExone Biologic go public?

NurExone Biologic went public on the TSXV in July 2022.

What was a key recent intellectual property milestone for NurExone Biologic?

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing, strengthening its supply chain readiness.

What was the outcome of NurExone's preclinical study on spinal cord injury?

In September 2024, NurExone demonstrated an extended therapeutic window of ExoPTEN post spinal-cord injury in a preclinical study.

What regulatory designation did NurExone Biologic receive for its ExoPTEN therapy?

In October 2023, NurExone Biologic received FDA Orphan-Drug Designation, accelerating the development of its ExoPTEN therapy for Acute Spinal Cord Injury Treatment.